Prosecution Insights
Last updated: November 21, 2026
Application No. 17/422,346

IMPROVEMENT IN OR RELATING TO ORGANIC COMPOUNDS

Final Rejection §102§103§DOUBLEPATENT
Filed
Jul 12, 2021
Priority
Feb 04, 2019 — GB 1901500.7 +1 more
Examiner
GOTFREDSON, GAREN
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Givaudan S.A.
OA Round
6 (Final)
40%
Grant Probability
At Risk
7-8
OA Rounds
0m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants only 40% of cases
40%
Career Allowance Rate
219 granted / 550 resolved
-20.2% vs TC avg
Strong +28% interview lift
Without
With
+28.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
51 currently pending
Career history
612
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
40.8%
+0.8% vs TC avg
§102
15.3%
-24.7% vs TC avg
§112
21.1%
-18.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 550 resolved cases

Office Action

§102 §103 §DOUBLEPATENT
DETAILED ACTION Claims 1, 3, 5-11, 14, and 16 are pending. Of these, claim 11 is withdrawn as directed to a nonelected invention. Therefore, claims 1, 3, 5-10, 14, and 16 are under consideration on the merits. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Rejections The 103 rejections are maintained. The double patenting rejection is maintained. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 5, 7-10, and 14 are rejected under 35 U.S.C. 103 as unpatentable over Watanabe et al. (EP 1 023 842 B1; published 8.2.2000; of record in IDS) in view of McPherson et al (US Pat. Pub. 2006/0029705; published 2.9.2006; of record in IDS), and Warr et al. (US Pat. Pub. 2008/0241201; of record). As to claims 1, 5, 7-10, and 14, Watanabe discloses a powder composition (i.e., in “particulate form” as recited by claim 10), the composition comprising a functional substance such as a coloring agent (“cosmetic ingredient” of claim 1) or perfume such as lemon essential oil, wherein the composition further can comprise a hemicellulose and a starch or a starch hydrolysate or starch derivative such as a dextrin (a “water-soluble modified starch” of claim 1 that is a “maltodextrin” of claim 5)(paragraphs 11 and 17 and claim 1 of Watanabe). The hemicellulose is present in the amount of 5 to about 60 wt%, which is slightly above the ranges recited by claims 1 and 9 (paragraph 15). Watanabe discloses an embodiment wherein the lemon perfume is present in the amount of 20g/100g total weight of the composition, or 20%, which is below the ranges recited by claims 1 and 7. The composition is made by preparing an emulsion comprising the ingredients followed by drying (paragraph 19 and claim 8 of Watanabe), which the skilled artisan would recognize will result in an encapsulated composition wherein the perfume is entrapped within a matrix comprising the other ingredients. As to claim 8, Watanabe discloses an embodiment wherein the starch is present in the amount of 60 wt%, which is within the range recited by the claim (Example 1 at paragraph 22). The composition may be incorporated into drinks, foods, and cosmetics (paragraph 20), all of which are consumer products as recited by claim 14. As to claims 1, 5, 7-10, and 14, Watanabe does not further expressly disclose that the hemicellulose is present in amounts within the ranges of claim 1 or 9, or that the water-soluble modified starch is one of those recited by claim 1, such as starch sodium octenyl succinate, nor that the amount of the perfume or cosmetic ingredient is within the 30-50 wt% range of claims 1 or 7. Warr discloses perfume compositions for use in personal care formulations (paragraph 2), wherein a water-soluble modified starch such as starch octenyl succinate is used as an encapsulating matrix (paragraphs 16 and 64). Warr further discloses the use of many ingredients in the form of their sodium salts such as sodium carboxylates, sodium citrate, sodium silicate, sodium disilicate, sodium carbonate, and sodium sulphate including sodium salts of polysaccharides (i.e., sodium carboxymethyl cellulose)(see, e.g., Examples 12-16). McPherson discloses an emulsion composition comprising an essential oil such as citrus oil (both a “cosmetic ingredient” and a “perfume” of claim 1)(paragraph 2) as a flavor agent, wherein the citrus oil is encapsulated in a matrix comprising a hemicellulose and starch (paragraphs 10-11, 16, 29). McPherson teaches that the hemicellulose is an efficient emulsifier of essential oils (paragraph 8). The hemicellulose may be used in any amount effective to emulsify the oil, with a typical range of 1-15 wt%, which encompasses or overlaps the ranges of claims 1 and 9 (paragraph 31). The composition typically comprises the starch in the amount of about 5-25 wt%, which is slightly below the range of claim 8 (paragraph 16). Warr discloses perfume compositions for use in personal care formulations (paragraph 2), wherein a water-soluble modified starch such as starch octenyl succinate is used as an encapsulating matrix (paragraphs 16 and 64). Warr further discloses the use of many ingredients in the form of their sodium salts such as sodium carboxylates, sodium citrate, sodium silicate, sodium disilicate, sodium carbonate, and sodium sulphate including sodium salts of polysaccharides (i.e., sodium carboxymethyl cellulose)(see, e.g., Examples 12-16). As to claims 1, 5, 7-10, and 14, it would have been prima facie obvious to one of ordinary skill in the art at the effective filing date of the present invention to modify the encapsulated perfume starch matrix composition of Watanabe by optimizing the amount of the perfume to arrive at an amount that is within the range recited by claims 1 and 7, because the amount of the perfume is a result effective variable that will affect the ability of the composition to impart a desired fragrance to cosmetics. The Office notes that the function of the perfume is the same in the Watanabe composition as in the present composition, i.e., imparting a fragrance to a personal care composition (see, e.g., paragraph 2 of the present specification as published), such that the skilled artisan would have been optimizing the amount of the perfume in the Watanabe composition to achieve the same intended function as the perfume in the present invention, and therefore would have had a reasonable expectation of success in arriving at the claimed range. Discovering optimum or working ranges involves only routine skill in the art in cases where the general conditions of a claim are disclosed in the prior art. In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Here, there is no evidence of record that the claimed range is critical in nature. It further would have been prima facie obvious to optimize the amount of the hemicellulose to arrive at an amount that is within the ranges recited by claims 1 and 9, because McPherson expressly teaches that such amounts are useful for combining with a starch to form a matrix that encapsulates an active ingredient such that the skilled artisan reasonably would have expected that such an amount would be suitable for use in the Watanabe composition, and additionally because differences in concentration generally will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Additionally, the amount of hemicellulose is a result effective variable that will affect its ability to emulsify the composition and encapsulate the citrus oil. It further would have been prima facie obvious to modify the encapsulated perfume starch matrix composition of Watanabe by selecting starch sodium octenyl succinate as a starch present in the encapsulating matrix, instead of, or in addition to, one of the starch and starch derivatives taught by Watanabe, because Warr expressly teaches that starch octenyl succinate is suitable for use in forming a starch matrix for encapsulating a perfume, such that the skilled artisan reasonably would have expected that it could function as a component of the starch matrix of the Watanabe encapsulated perfume composition. Such a modification is merely the substitution of one known element for another according to known methods to yield predictable results, which is prima facie obvious. MPEP 2143. Using the sodium salt of starch octenyl succinate is viewed as an obvious variation because it standard practice for the skilled artisan to formulate organic compounds in the form of their salts such as their sodium salts for inclusion in personal care compositions, as demonstrated by Watanabe’s own disclosure of using numerous ingredients, including another polysaccharide (i.e., carboxymethyl cellulose) in the form of its sodium salt. Claim 3 is rejected under 35 U.S.C. 103 as unpatentable Watanabe et al. (EP 1 023 842 B1) in view of McPherson et al (US Pat. Pub. 2006/0029705) and Warr et al. (US Pat. Pub. 2008/0241201) as applied to claims 1, 5, 7-10, and 14 above, and further in view of Nie et al. (Dermatol Res Pract. 2013l of record). The teachings of Watanabe, McPherson, and Warr are relied upon as discussed above, but they do not further expressly disclose that the hemicellulose is a xyloglucan as recited by claim 3. Nie discloses that xyloglucans are one of the two major hemicelluloses found in plant primary walls, and that xyloglucans obtained from tamarind seed have wound healing properties due to their ability to improve processes of reepithelization and remodeling (Abstract and Section 5). As to claim 3, it would have been prima facie obvious to one of ordinary skill in the art at the effective filing date of the present invention to modify the encapsulated perfume starch matrix composition of Watanabe, McPherson, and Warr as combined supra by selecting xyloglucans as the type of water soluble hemicellulose, because Watanabe does not teach that the hemicellulose must be obtained from any particular source, and Nie discloses that xyloglucan hemicelluloses can be obtained from tamarind seeds and are useful for their skin-health promoting properties, such that the skilled artisan would have had a motivation to use them as the hemicellulose in the Watanabe composition with a reasonable expectation of success. Such a modification is merely the substitution of one known element for another according to known methods to yield predictable results, which is prima facie obvious. MPEP 2143. Claims 6 and 16 are rejected under 35 U.S.C. 103 as unpatentable over Watanabe et al. (EP 1 023 842 B1), McPherson et al. (US Pat. Pub. 2006/0029705), and Warr et al. (US Pat. Pub. 2008/0241201 as applied to claims 1, 5, 7-10, and 14 above, and further in view of Smets et al. (U.S. Pat. No. 2015/0099680; of record in IDS). The teachings of Watanabe, McPherson, and Warr are relied upon as discussed above, but they do not further expressly disclose that the composition comprises a flowing agent that is among those recited by claims 6 and 16, such as zeolites. Smets discloses a composition comprising particles for delivering a benefit agent such as a perfume, the particles comprising a material that encapsulates a core material (paragraphs 1-2 and 5), wherein the composition may comprise zeolites as detergent builders or as carriers for the perfume to reduce the amount of free perfume (paragraphs 240 and 260), as well as xyloglucan polymers obtained from tamarind for use as thickening stabilizers (paragraph 247). As to claims 6 and 16, it would have been prima facie obvious to one of ordinary skill in the art at the effective filing date of the present invention to modify the encapsulated perfume starch matrix composition of Watanabe, McPherson, and Warr by incorporating zeolites to serve as carriers for the perfume or alternatively as a builder when the composition is intended to be used in a detergent, because Smets teaches that zeolites are useful as carriers for perfume in compositions comprising particles for use in delivering a perfume and are also useful as detergent builders. Such a modification is merely the combination of known elements according to known methods to yield predictable results, which is prima facie obvious. MPEP 2143. Response to Applicant’s Arguments Applicant argues that the amount of hemicellulose disclosed by Watanabe and used in the working examples therein is above the range of claim 1. Applicant argues that McPherson’s disclosure of 1-15 wt% hemicellulose is based on the total weight of the aqueous emulsion and not on the final dry encapsulated composition, and that based on this disclosure the dry weight percent would be above the claimed maximum of 2 wt%. In response, it would have been obvious to select an amount of the entrapped perfume ingredient and of the hemicellulose that is within the claimed ranges via an optimization process as discussed in the rejection and further because McPherson teaches amounts of the hemicellulose that are within the claimed range as discussed in the rejection. The amount of hemicellulose recited by the claims is prima facie obvious over the cited art regardless of whether the weight percents of McPherson are with respect to the emulsion or to the dry weight, because, as discussed in the rejection, the amount of hemicellulose is a result effective variable that will affect its ability to emulsify the composition and encapsulate the citrus oil and differences in concentration generally will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). The amounts disclosed by McPherson would have provided the skilled artisan with a starting point for an optimization process for the hemiceullose in the Watanabe composition. Applicant argues that Watanabe is not relevant as a prior art reference because it makes it clear that the presence of trehalose is essential to the invention taught therein as shown in Examples 1-6 of Watanabe. In response, this is not persuasive because the language of the present claims does not exclude the presence of trehalose. Applicant also argues that none of Watanabe's examples comprise hemicellulose in combination with a dextrin modified starch. In response, this is not persuasive because the broader disclosure of Watanabe teaches that a starch or starch derivative such as dextrin can be used as discussed in the rejection. Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. MPEP 2123. In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971). Applicant argues that Nie would not be considered by the skilled artisan in combination with McPherson, as it is allegedly not relevant to the technical problem faced by Applicant because it includes no suggestion of any information which a skilled artisan would recognize as relating to entrapment of a perfume and/or cosmetic ingredient in a matrix, a suggestion that Applicant asserts is found in Applicant’s specification, but not in the cited art. In response, the Office notes that whether or not the prior art is concerned with the same technical problem as Applicant is not relevant to a 103 analysis. The skilled artisan looking for water soluble hemicelluloses that would be suitable for use in the McPherson cosmetic composition would consider relevant any prior art disclosing the use of water soluble hemicelluloses in cosmetic compositions, which would include Nie. Therefore, Nie is viewed as a reference that would be considered relevant to the skilled artisan when looking to modify the disclosure of McPherson. Applicant argues that Smets uses a core shell encapsulation technology that is completely different than water soluble starch encapsulation, such that the skilled artisan would not have looked to this reference. In response, the rejection does not rely on the core shell encapsulation technology taught by Smets, but rather on its teaching that zeolites are useful as carriers for delivering a benefit agent such as perfume. The skilled artisan therefore would have found Smets relevant to Watanabe because Watanabe discloses a composition for delivering perfume. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 1, 3, 5-10, 14, and 16 are provisionally rejected on the ground of nonstatutory double patenting as unpatentable over all claims of U.S. Pat. Appl. No. 19/483,443 and in view of Watanabe et al. (EP 1 023 842 B1), McPherson et al (US Pat. Pub. 2006/0029705), Nie et al. (Dermatol Res Pract. 2013), and/or Smets et al. (U.S. Pat. No. 2015/0099680) where indicated below. The teachings of the cited secondary references are relied upon as discussed above. The reference claims recite a consumer product composition comprising 54-85 wt% of a fragrance, the fragrance being encapsulated in core/shell particles comprising a matrix comprising a starch such as starch sodium octenyl succinate along with a hemicellulose and maltodextrin or mannitol. Although the reference claims do not recite the presence of a flowing agent such as zeolites, it would have been prima facie obvious to incorporate zeolites to serve as carriers for the perfume or alternatively as a builder when the composition is intended to be used in a detergent, because Smets teaches that zeolites are useful as carriers for perfume in compositions comprising particles for use in delivering a perfume and are also useful as detergent builders. Such a modification is merely the combination of known elements according to known methods to yield predictable results, which is prima facie obvious. MPEP 2143. Although the reference claims do not recite the claimed amount of the hemicellulose, It further would have been prima facie obvious to optimize the amount of the hemicellulose to arrive at an amount that is within the ranges recited by claims 1 and 9, because McPherson expressly teaches that such amounts are useful for combining with a starch to form a matrix that encapsulates an active ingredient such that the skilled artisan reasonably would have expected that such an amount would be suitable for use in the reference composition, and additionally because differences in concentration generally will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). Additionally, the amount of hemicellulose is a result effective variable that will affect its ability to emulsify the composition and encapsulate the citrus oil. Although the reference claims do not recite the claimed amount of the starch, it further would have been prima facie obvious to select such an amount, because Watanabe discloses that the starch used to form a matrix along with a hemicellulose for encapsulation of a fragrance suitably may be present in amounts within the range recited by the claims Although the reference claims do not recite that the hemicellulose is a xyloglucan, it would have been prima facie obvious to one of ordinary skill in the art at the effective filing date of the present invention to select xyloglucans as the type of water soluble hemicellulose, because Nie discloses that xyloglucan hemicelluloses obtained from tamarind seeds are useful for their skin-health promoting properties, such that the skilled artisan would have had a motivation to use them as the hemicellulose in the reference composition with a reasonable expectation of success. Such a modification is merely the substitution of one known element for another according to known methods to yield predictable results, which is prima facie obvious. MPEP 2143. The claims are directed to an invention not patentably distinct from the claims of the copending application. Specifically, see above. The USPTO may not institute a derivation proceeding in the absence of a timely filed petition. The U.S. Patent and Trademark Office normally will not institute a derivation proceeding between applications or a patent and an application of common ownership (see 37 CFR 42.411). The copending application, discussed above, would be prior art to the noted claims under 35 U.S.C. 102(a)(2) if the patentably indistinct inventions were not commonly owned or deemed to be commonly owned as of the effective filing date under 35 U.S.C. 100(i) of the claimed invention. In order for the Examiner to resolve this issue the applicant or patent owner can provide a statement under 35 U.S.C. 102(b)(2)(C) and 37 CFR 1.104(c)(4)(i) to the effect that the subject matter and the claimed invention, not later than the effective filing date of the claimed invention, were owned by the same person or subject to an obligation of assignment to the same person. Alternatively, the applicant or patent owner can provide a statement under 35 U.S.C. 102(c) and 37 CFR 1.104(c)(4)(ii) to the effect that the subject matter was developed and the claimed invention was made by or on behalf of one or more parties to a joint research agreement that was in effect on or before the effective filing date of the claimed invention, and the claimed invention was made as a result of activities undertaken within the scope of the joint research agreement; the application must also be amended to disclose the names of the parties to the joint research agreement. A showing that the inventions were commonly owned or deemed to be commonly owned as of the effective filing date under 35 U.S.C. 100(i) of the claimed invention will preclude a rejection under 35 U.S.C. 102 or 103 based upon the commonly assigned case. Response to Applicant’s Arguments Applicant argues that the copending application relates to a composition comprising a water soluble matrix and a benefit agent that is at least partially encapsuled in core shell microcapsules while the present application relates to an encapsulated composition entrapped in a matrix, and that the present application makes a clear distinction between the technical effect achieved by the present invention compared with core-shell microcapsules. In response, this argument is not persuasive because the structure of the composition of the reference claims reads on the structure of the present claims for the reasons discussed in the rejection, and Applicant has not explained how the structure of the claims is not obvious in view of the structure of the reference claims Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GAREN GOTFREDSON whose telephone number is (571)270-3468. The examiner can normally be reached M-F 9AM-6PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, David Blanchard can be reached on 5712720827. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GAREN GOTFREDSON/Examiner, Art Unit 1619 /ANNA R FALKOWITZ/Primary Examiner, Art Unit 1600
Read full office action

Prosecution Timeline

Show 9 earlier events
Aug 06, 2025
Response Filed
Dec 05, 2025
Final Rejection mailed — §102, §103, §DOUBLEPATENT
Mar 03, 2026
Response after Non-Final Action
Apr 17, 2026
Request for Continued Examination
Apr 20, 2026
Response after Non-Final Action
May 18, 2026
Non-Final Rejection mailed — §102, §103, §DOUBLEPATENT
Aug 17, 2026
Response Filed
Nov 09, 2026
Final Rejection mailed — §102, §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797416
SPHEROIDS FOR SUPPRESSING IMMUNE REJECTION AND USES THEREOF
4y 0m to grant Granted Nov 17, 2026
Patent 12678441
METHOD OF MAKING COMPOSITION INCLUDING ENCAPSULATED CAFFEINE
5y 1m to grant Granted Jul 14, 2026
Patent 12667537
Personal Care Compositions Comprising Cannabidiol and Licorice
5y 3m to grant Granted Jun 30, 2026
Patent 12636256
STARCH FILM-FORMING COMPOSITIONS AND METHODS OF THEIR USE FOR PREPARING CAPSULE SHELLS
3y 10m to grant Granted May 26, 2026
Patent 12622998
LIQUID DRESSING
4y 2m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
40%
Grant Probability
68%
With Interview (+28.2%)
3y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 550 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month